Travere Therapeutics ( (TVTX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Travere Therapeutics’ stock has seen a downturn, even though the FDA’s cancellation of an advisory committee meeting for FILSPARI suggests confidence in its approval. Analysts have increased the price target, thanks to strong clinical data and fewer regulatory obstacles, boosting FILSPARI’s market potential. Nonetheless, mixed regulatory sentiment and ongoing financial challenges are still impacting the stock negatively.
More about Travere Therapeutics
YTD Price Performance: 43.96%
Average Trading Volume: 1,816,740
Technical Sentiment Signal: Buy
Current Market Cap: $2.43B
For further insights into TVTX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.